UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab

The European respiratory journal, 2015-12, Vol.46 (6), p.1740-1750

2015

Volltextzugriff (PDF)

Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof‐of‐concept study

Hepatology (Baltimore, Md.), 2016-07, Vol.64 (1), p.189-199

2016

Volltextzugriff (PDF)

Modification of the Fc Region of a Human Anti‐oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half‐life in Cynomolgus Monkeys

Basic & clinical pharmacology & toxicology, 2017-07, Vol.121 (1), p.13-21

2017

Volltextzugriff (PDF)

Non‐Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First‐in‐Human Dose Selection for CNTO 5825, an Anti‐Interleukin‐13 Monoclonal Antibody

Basic & clinical pharmacology & toxicology, 2015-10, Vol.117 (4), p.219-225

2015

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ‐61178104, a Novel Tumor Necrosis Factor‐Alpha and Interleukin‐17A Bispecific Antibody, in Healthy Subjects

Journal of clinical pharmacology, 2019-07, Vol.59 (7), p.968-978

2019

Volltextzugriff (PDF)

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A

mAbs, 2020-01, Vol.12 (1), p.1770018

2020

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-β1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants

Clinical pharmacokinetics, 2016-02, Vol.55 (2), p.225-236

2016

Volltextzugriff (PDF)

Safety, tolerability and pharmacokinetics of a human anti‐interleukin‐13 monoclonal antibody (CNTO 5825) in an ascending single‐dose first‐in‐human study

British journal of clinical pharmacology, 2013-05, Vol.75 (5), p.1289-1298

2013

Volltextzugriff (PDF)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Blood cancer journal (New York), 2023-03, Vol.13 (1), p.33-33, Article 33

2023

Volltextzugriff (PDF)

Unexpected Toxicology Findings in Rats Dosed With an Antihuman IL-13 Monoclonal Antibody

International journal of toxicology, 2015-09, Vol.34 (5), p.393-407

2015

Volltextzugriff (PDF)

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate

Annals of the rheumatic diseases, 2017-05, Vol.76 (5), p.831-839

2017

Volltextzugriff (PDF)

Novel 17-Azolyl Steroids, Potent Inhibitors of Human Cytochrome 17α-Hydroxylase-C17,20-lyase (P45017 α): Potential Agents for the Treatment of Prostate Cancer

Journal of medicinal chemistry, 1998-03, Vol.41 (6), p.902-912

1998

Volltextzugriff (PDF)

Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review

Clinical pharmacology and therapeutics, 2023-05, Vol.113 (5), p.1011-1029

2023

Volltextzugriff (PDF)

The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retrorsine-induced hepatotoxicity in rats

Toxicon (Oxford), 1999-09, Vol.37 (9), p.1259-1270

1999

Volltextzugriff (PDF)

The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis

British journal of clinical pharmacology, 2020-12, Vol.86 (12), p.2507-2518

2020

Volltextzugriff (PDF)

Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma

British journal of clinical pharmacology, 2023-05, Vol.89 (5), p.1640-1655

2023

Volltextzugriff (PDF)

Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study

BLOOD, 2021-11, Vol.138 (Supplement 1), p.1667-1667

2021

Volltextzugriff (PDF)

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model

The Journal of steroid biochemistry and molecular biology, 2004-10, Vol.92 (3), p.155-165

2004

Volltextzugriff (PDF)

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Leukemia & lymphoma, 2023-01, Vol.64 (2), p.468-472

2023

Volltextzugriff (PDF)

Involvement of cytochrome P450 and the flavin-containing monooxygenase(s) in the sulphoxidation of simple sulphides in human liver microsomes

Life sciences (1973), 2003-06, Vol.73 (3), p.359-369

2003

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis

Journal of clinical pharmacology, 2022-05, Vol.62 (5), p.656-669

2022

Volltextzugriff (PDF)

Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)

Blood, 2019-11, Vol.134 (Supplement_1), p.1876-1876

2019

Volltextzugriff (PDF)

Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004-10, Vol.810 (2), p.203-208

2004

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(41)

Publikationsform

Sprache

Englisch
(47)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Humans
(21)
Male
(19)
Pharmacology & Pharmacy
(19)
Animals
(16)
Biological And Medical Sciences
(11)
Pharmacokinetics
(11)
Medical Sciences
(10)
Rats
(9)
Female
(8)
Pharmacology. Drug Treatments
(8)
Antibodies, Monoclonal - Pharmacokinetics
(7)
Chromatography, High Pressure Liquid
(7)
Middle Aged
(7)
Administration, Intravenous
(6)
Adult
(6)
Multiple Myeloma - Drug Therapy
(6)
Oncology
(6)
Treatment Outcome
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab

Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof‐of‐concept study

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

Modification of the Fc Region of a Human Anti‐oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half‐life in Cynomolgus Monkeys

Non‐Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First‐in‐Human Dose Selection for CNTO 5825, an Anti‐Interleukin‐13 Monoclonal Antibody

Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ‐61178104, a Novel Tumor Necrosis Factor‐Alpha and Interleukin‐17A Bispecific Antibody, in Healthy Subjects

Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A

Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-β1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants

Safety, tolerability and pharmacokinetics of a human anti‐interleukin‐13 monoclonal antibody (CNTO 5825) in an ascending single‐dose first‐in‐human study

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Unexpected Toxicology Findings in Rats Dosed With an Antihuman IL-13 Monoclonal Antibody

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate

Novel 17-Azolyl Steroids, Potent Inhibitors of Human Cytochrome 17α-Hydroxylase-C17,20-lyase (P45017 α): Potential Agents for the Treatment of Prostate Cancer

Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review

The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retrorsine-induced hepatotoxicity in rats

The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis

Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma

Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Involvement of cytochrome P450 and the flavin-containing monooxygenase(s) in the sulphoxidation of simple sulphides in human liver microsomes

Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis

Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)

Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection

Suchergebnisse filtern